Hypertension is the most common cardiovascular risk factor in older adults, significantly contributing to morbidity and mortality. Its prevalence rises with age and is strongly associated with vascular aging, isolated systolic hypertension, and comorbidities, such as cognitive impairment and chronic kidney disease. However, treatment in older adults—especially those with frailty—requires a careful balance between benefit and potential harm. This review aimed to provide an updated synthesis of pathophysiological mechanisms, epidemiological trends, diagnostic considerations, and evidence‑based therapeutic approaches to arterial hypertension in older adults. Emphasis was placed on tailoring treatment strategies according to frailty and functional status. We conducted a narrative review of major international guidelines (European Society of Cardiology, European Society of Hypertension), clinical trials, and real‑world studies addressing hypertension in aging populations. Special focus was given to randomized controlled trials and observational studies stratified by frailty. Evidence supports blood pressure lowering in fit older adults, as demonstrated in trials such as HYVET, SPRINT‑SENIOR, and STEP, which showed significant reductions in cardiovascular events and mortality. Conversely, some studies (eg, PARTAGE, OPTiMiSE, and DANTE) highlighted the risks of overtreatment in frail or institutionalized patients, including hypotension, falls, and increased mortality. The presence of orthostatic hypotension, impaired renal function, and polypharmacy further complicates management. In conclusion, hypertension management in the elderly should follow a personalized approach based on a comprehensive geriatric assessment and frailty evaluation; patient‑centered goals are essential to guide treatment intensity, aiming to protect cardiovascular health without compromising safety, cognition, or functional independence. Future studies must include frailer populations to better inform clinical decisions.

How to effectively treat arterial hypertension in elderly individuals?

Giani A;Zoico E;Zamboni M
2025-01-01

Abstract

Hypertension is the most common cardiovascular risk factor in older adults, significantly contributing to morbidity and mortality. Its prevalence rises with age and is strongly associated with vascular aging, isolated systolic hypertension, and comorbidities, such as cognitive impairment and chronic kidney disease. However, treatment in older adults—especially those with frailty—requires a careful balance between benefit and potential harm. This review aimed to provide an updated synthesis of pathophysiological mechanisms, epidemiological trends, diagnostic considerations, and evidence‑based therapeutic approaches to arterial hypertension in older adults. Emphasis was placed on tailoring treatment strategies according to frailty and functional status. We conducted a narrative review of major international guidelines (European Society of Cardiology, European Society of Hypertension), clinical trials, and real‑world studies addressing hypertension in aging populations. Special focus was given to randomized controlled trials and observational studies stratified by frailty. Evidence supports blood pressure lowering in fit older adults, as demonstrated in trials such as HYVET, SPRINT‑SENIOR, and STEP, which showed significant reductions in cardiovascular events and mortality. Conversely, some studies (eg, PARTAGE, OPTiMiSE, and DANTE) highlighted the risks of overtreatment in frail or institutionalized patients, including hypotension, falls, and increased mortality. The presence of orthostatic hypotension, impaired renal function, and polypharmacy further complicates management. In conclusion, hypertension management in the elderly should follow a personalized approach based on a comprehensive geriatric assessment and frailty evaluation; patient‑centered goals are essential to guide treatment intensity, aiming to protect cardiovascular health without compromising safety, cognition, or functional independence. Future studies must include frailer populations to better inform clinical decisions.
2025
antihypertensive therapy
clinical trials
elderly
frailty
hypertension
File in questo prodotto:
File Dimensione Formato  
Fantin et al Pol Arch Intern Med.pdf

accesso aperto

Descrizione: full text
Tipologia: Versione dell'editore
Licenza: Dominio pubblico
Dimensione 342.64 kB
Formato Adobe PDF
342.64 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1182853
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact